BRILife®

NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research

Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus Data Suggest that the BriLife Vaccine May Be Capable of Evolving to Counter Delta and Other Variants of Concern NRx […]

NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results

RADNOR, Pa., Nov 16, 2021 /PRNewswire/ — NRx Pharmaceuticals  (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results. […]

NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Production

NRx Enters into Negotiations for Financing and Manufacturing Capacity with BNP Paribas to serve European and Adjacent Markets Tech Transfer and Scaleup of BriLife™ COVID-19 Vaccine to Commence in November 2021 Targeting Initiation of GMP Vaccine Manufacture in First Half of 2022 RADNOR, Pa., Nov. 5, 2021 /PRNewswire/ — NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), […]